The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.
about
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myelomaNovel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)The Role of Immunotherapy in Multiple MyelomaCurrent status of immunotherapyImmunostimulatory Gene Therapy Using Oncolytic Viruses as VehiclesCAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in LymphomaLenalidomide and chronic lymphocytic leukemiaImmune reconstitution in chronic lymphocytic leukemiaImmunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemiaNew drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapyImmunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patientsGM-CSF Down-Regulates TLR Expression via the Transcription Factor PU.1 in Human MonocytesDevelopments in HIV-1 immunotherapy and therapeutic vaccination.Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.Pomalidomide is active in the treatment of anemia associated with myelofibrosisImmunomodulatory agents in myelofibrosis.Lenalidomide for the treatment of relapsed and refractory multiple myeloma.Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myelomaPomalidomide in myeloproliferative neoplasm-associated myelofibrosis.Immune checkpoint blockade for hematologic malignancies: a reviewCombination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer modelEffect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.Vaccines against human carcinomas: strategies to improve antitumor immune responses.Lenalidomide enhances anti-myeloma cellular immunityImmunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF.Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.A review of the history, properties, and use of the immunomodulatory compound lenalidomide.A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case reportImmunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myelomaIncreased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma.NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.Modest activity of pomalidomide in patients with myelofibrosis and significant anemiaEffect of immunoglobulin therapy on the rate of infections in multiple myeloma patients undergoing autologous stem cell transplantation or treated with immunomodulatory agentsSafety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report.Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemiaMechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.Lenalidomide-induced acute interstitial nephritis
P2860
Q24605861-EB37D3A7-1AE0-45FA-9614-C22DC2F40AF9Q26770391-1E0148DF-FD06-46A3-9261-1EF34454B25EQ26771144-E2FB68EE-AF53-4F82-92D5-4A3DA85E909EQ26773314-6130C288-9BCD-4594-ADB5-2B92EBCE62FBQ26777403-845E52F5-A3FF-4BA7-91F9-D2C921553620Q26800814-D45675AF-4015-410B-99A3-C8C542D6F149Q26823597-605DBDE6-1400-4CF6-908E-786A78567650Q26865561-64553DD5-3CA5-4FB8-B19A-B760AA6ABA90Q27001318-92F11749-936E-4A71-9E9E-AB4C0B7D1753Q27004421-FD6E8B4A-1E48-4E0E-9CB0-FE213109C8A0Q27008625-F060D30B-BA3A-4011-94C1-51F1BC3DFB2DQ28534976-F8C8EC1D-B762-4F3E-8850-8BD877E9DA8BQ28554454-3AC4D6C2-47F9-4712-9412-4527090C3088Q30364312-AF4EFF22-B8F8-459C-B8C4-709E63EA98CDQ30802505-5740FA51-9F0A-41BA-9BCF-625261A03F98Q33385644-DC8EA70D-5199-43A0-BE1A-45FD40337E0AQ33401615-C5EACF92-6999-47D2-B87F-5B7D65155AD8Q33403183-55F05391-A8A5-4F00-BCC4-15D6A4C27200Q33413142-4D975F27-0F8C-4A88-90E3-514C0E1D2AF0Q33436247-A8FC316D-048B-4106-9A5D-3DBB2CBA1A54Q33645590-DE497EA0-6537-467D-8C0F-780924209637Q33689002-D794EAE9-1C56-49D4-8F6A-DD658E9CDD91Q33707411-26802FD3-1332-4DC1-8AAF-87F93AFEDF2CQ33734281-AF7245D3-D1A0-4F5D-937D-D13B6A186391Q33903133-31B4C269-72F3-4842-8EA9-3CDC20EFC136Q33960866-A15BD327-ABD2-4192-8DBA-4B4828806D02Q34172063-12E61793-2C76-45DC-9737-5E0158770780Q34173071-29985E68-F9C1-4472-B837-481351E4219AQ34220013-2479D941-0B9D-4D01-9CE0-378A22BD813CQ34314074-A5B080F2-24F5-4EB7-9E4F-E847B6DE77DBQ34369823-A6E34B99-1B8F-4BAC-AACD-1D0A36C8966AQ34447864-B26B9506-DD11-4481-BBB2-64B67C9F9F14Q34485950-F82D6488-8633-4067-AAB5-FA05EE1DD37DQ34512203-7C99B6A1-764E-42F1-B091-EFB2C638084AQ34549211-6C691FF8-E20C-456B-932C-7D6C56BF81A7Q34666858-E1191F11-D786-4B96-8644-487D585F5F9AQ35064910-B2FAEDE6-C798-4334-BCF4-71A1FBB22D9BQ35146081-F1FD029C-D332-459C-88C0-EACB8719C0CDQ35171777-AEFA0129-90C9-4EEB-9021-D31BBE435BD2Q35584263-66F66626-E812-459F-B6DF-93E358503FC1
P2860
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
The anti-cancer agents lenalid ...... unction of T regulatory cells.
@en
The anti-cancer agents lenalid ...... unction of T regulatory cells.
@nl
type
label
The anti-cancer agents lenalid ...... unction of T regulatory cells.
@en
The anti-cancer agents lenalid ...... unction of T regulatory cells.
@nl
prefLabel
The anti-cancer agents lenalid ...... unction of T regulatory cells.
@en
The anti-cancer agents lenalid ...... unction of T regulatory cells.
@nl
P2093
P2860
P1476
The anti-cancer agents lenalid ...... function of T regulatory cells
@en
P2093
Angus G Dalgleish
Brendan Meyer
Christine Galustian
David Stirling
Deborah Klaschka
George Muller
J Blake Bartlett
Jake Henry
Keith Dredge
Marie-Christine Labarthe
P2860
P2888
P304
P356
10.1007/S00262-008-0620-4
P577
2008-11-14T00:00:00Z